Nephrology - Filspari (sparsentan) coverage
Customize your policy alerts
Sign up for Cigna Policy IP0565 alerts
Get alerted when Policy IP0565 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization, medical necessity criteria, and coverage decisions for Filspari (sparsentan) for Cigna-administered health benefit plans, addressing FDA indications for FSGS and primary IgA nephropathy and who may prescribe and monitor therapy.
Focal Segmental Glomerulosclerosis was added as a new condition of approval.
High-risk progression proteinuria threshold for Primary IgA Nephropathy was modified multiple times, most recently to urine protein-to-creatinine ratio ≥ 0.5 g/g OR proteinuria ≥ 0.5 g/day.
Added condition not recommended for approval: concurrent use with other medications indicated for IgA nephropathy (e.g., Fabhalta and Vanrafia).
Documentation requirements were added for Primary IgA Nephropathy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.